Navigation Links
Uroplasty Announces Addition of Robert Kill to its Board of Directors
Date:12/8/2010

MINNEAPOLIS, Dec. 8, 2010 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors.  Mr. Kill's appointment increases the membership on the Board to seven.

Mr. Kill (46) is the President, CEO and a Board member of Virtual Radiologic Corporation, a Minneapolis-based, high growth provider of teleradiology and technology solutions to radiology practices and hospitals throughout the United States.  Prior to joining Virtual Radiologic, Mr. Kill served as President of the Physicians Systems business at Misys Healthcare, a developer of healthcare software systems.  Earlier, he spent 10 years with Baxter Healthcare, where he held senior leadership positions in operations, marketing and sales.  He holds a B.A. in Economics from the University of Notre Dame.

"We are very pleased to have Rob join our Board at this key time at Uroplasty," said Patrick Maxwell, Chairman of the Board.  "His 19 years of experience with growing medical products and service companies will be extremely valuable to us as we execute our strategy to drive revenue growth and enhance valuation for our shareholders."

"I am excited to join Uroplasty's Board as the Company re-launches its Urgent PC Neuromodulation System in the U.S. for the treatment of overactive bladder," said Mr. Kill.  "I believe that my experience in a high growth environment will be of value to Uroplasty's Board and shareholders during this pivotal time in the Company's development."

David Kaysen, President and CEO of Uroplasty said, "Rob brought Virtual Radiologic public, growing it several fold in four years, and then sold the company in a private transaction.  As we roll out the re-launch plans for Urgent PC, and prepare for our growth, Rob's skills and expertise will be invaluable in dealing with the challenges and opportunities ahead of us."  

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140


EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
2. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
3. Uroplasty Reports Financial Results for the Second Quarter FY2011
4. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
5. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
6. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
7. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
8. Uroplasty Reports Results for Second Quarter FY2010
9. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Hemophilia market? ...
(Date:2/24/2017)... Feb. 24, 2017  In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Tuesday, March 14, 2017 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and Associated ... Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss any ... into a single volume a compelling argument that the disease does exist in his ...
(Date:2/27/2017)... ... 27, 2017 , ... Silicon Valley Hair Institute, a professional ... upgrade to the company's Yelp listing. Bay Area residents struggling from thinning hair ... Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit Extraction ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... the lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for ... analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements ...
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
(Date:2/25/2017)... Aliso Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... luminance with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have ... alpha sliders to easily refine their color range. With color spectrum tools users can ...
Breaking Medicine News(10 mins):